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Abstract 
Inflammation has been reported to play an important role in cancer progression and various inflammatory mark-
ers have been reported to be useful prognostic markers. The aim of this retrospective study was to evaluate the 
significance of the C-reactive protein to albumin (CRP/ALB) ratio in colorectal cancer patients who received pallia-
tive chemotherapy. We performed a retrospective review of 99 patients who underwent palliative chemotherapy 
for unresectable colorectal cancer between 2005 and 2010. The cutoff value of the CRP/ALB ratio was determined 
based on a receiver operating characteristics curve analysis. The relationship between the CRP/ALB ratio and survival 
was assessed. The cutoff value for the CRP/ALB ratio was 0.183. The high pretreatment CRP/ALB ratio group showed 
significantly worse overall survival. Patients with a high pretreatment CRP/ALB ratio and in whom the CRP/ALB ratio 
normalized after chemotherapy tended to have better overall survival than those in whom both the pretreatment 
and posttreatment CRP/ALB ratios were high. The CRP/ALB ratio is a useful marker for predicting survival and monitor-
ing chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.
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Background
Colorectal cancer (CRC) is one of the most common 
causes of cancer-related death worldwide (Edwards et al. 
2014). Unresectable metastasis is one of the most impor-
tant prognostic factors for patients with CRC (Shibu-
tani et al. 2015b). In spite of advances in chemotherapy, 
which include new cytotoxic and molecular targeted 
therapies, the prognosis of patients with unresectable 
metastatic CRC remains poor, with a median survival 
time of approximately 30 months (Heinemann et al. 2014; 
Grothey et al. 2008). The assessment of prognostic factors 
is therefore important for the management of unresect-
able metastatic CRC patients.
It is well known that there is a close relationship 
between inflammation and cancer progression (Man-
tovani et  al. 2008; Balkwill and Mantovani 2001) and 
some inflammatory markers have been investigated as 
prognostic factors in CRC (Shibutani et  al. 2013, 2014; 
McMillan et al. 2007; Maeda et al. 2015). The C-reactive 
protein-to-albumin (CRP/ALB) ratio has been reported 
to be a more accurate prognostic value in patients with 
various malignancies than the modified Glasgow prog-
nostic score (mGPS) (Kinoshita et  al. 2015; Xu et  al. 
2015), which is also calculated from the serum CRP and 
ALB concentration, and we previously reported on the 
prognostic significance of the CRP/ALB ratio in patients 
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with CRC who underwent curative surgery (Shibutani 
et al. 2016). However, aside from our report, there have 
only been a few reports regarding the prognostic signifi-
cance of the CRP/ALB ratio in patients with CRC (Ishi-
zuka et al. 2016). Moreover, to the best of our knowledge, 
there are no published studies regarding the prognos-
tic significance of the CRP/ALB ratio in patients with 
unresectable metastatic CRC. Therefore, we applied this 
marker to patients with unresectable metastatic CRC and 
compared the usefulness of the CRP/ALB ratio with that 
of other inflammatory markers for predicting and moni-
toring the therapeutic outcome.
The aim of the present study is to evaluate the signifi-
cance of the CRP/ALB ratio as a marker for predicting 
survival and monitoring chemotherapeutic effectiveness 
in patients with unresectable metastatic CRC.
Methods
Patients
We retrospectively reviewed a database of 99 patients 
who underwent palliative combination chemotherapy for 
unresectable metastatic colorectal cancer at the Depart-
ment of Surgical Oncology of Osaka City University 
between 2005 and 2010.
The patient characteristics are listed in Table  1. The 
patient population consisted of 57 males and 42 females, 
with a median age of 63 years (range 27–86). Forty of the 
patients had metachronous unresectable cancer; 59 had 
synchronous unresectable cancer. Fifty-four patients 
had single organ metastasis and 45 patients multiple 
organs affected by metastases. All of the patients under-
went combination chemotherapy with oxaliplatin, or 
irinotecan plus 5-fluorouracil/leucovorin, or a prodrug 
of 5-fluorouracil as a first-line chemotherapy. Regi-
mens considered to have the same efficacy were used 
for all of the patients in this study (Cassidy et al. 2008; 
Tournigand et  al. 2004; Yamada et  al. 2013). Sixty-five 
patients received 5-fluorouracil  +  leucovorin  +  oxali-
platin (FOLFOX), 21 patients received capecit-
abine  +  oxaliplatin (CapeOX), nine patients received 
5-fluorouracil  +  leucovorin  +  irinotecan (FOLFIRI) 
and four patients received S-1  +  oxaliplatin (SOX). 
Sixty-nine patients underwent chemotherapy combined 
with molecular targeted therapy. The median follow-
up period for the surviving patients was 20.8  months 
(range 2.6–73.2 months). Sixty-three patients died dur-
ing the follow-up period.
Evaluation
Response evaluations were performed every eight weeks. 
A variation of approximately one week was regarded as 
an allowable error. All of the patients were followed up 
with a physical examination, blood tests (these included 
measurements of tumor marker levels such as carci-
noembryonic antigen [CEA]), computed tomography and 
ultrasonography.
The pretreatment blood samples were obtained within 
one week before the initiation of chemotherapy; the post-
treatment blood samples were obtained eight weeks after 
Table 1 The patients’ characteristics
FOLFOX 5-fluorouracil + leucovorin + oxaliplatin, CapeOX 
capecitabine + oxaliplatin, FOLFIRI 5-fluorouracil + leucovorin + irinotecan, 
SOX S-1 + oxaliplatin, CRP/ALB ratio C-reactive protein to albumin ratio, NLR 
neutriphil to lymphocyte ratio, mGPS modified Glasgow prognostic score
Age (years)








 Well, moderately 78
 Poorly, mucinous 12
 Unknown 9
Detection of unresectable tumor
 Synchronous 59
 Metachronous 40
The number of organs affected by metastasis
 One organ 54











The pretreatment C-reactive protein level
 Median (range) 0.32 (0.02–13.46)
The pretreatment albumin level
 Median (range) 3.9 (2.4–4.7)
The pretreatment CRP/ALB ratio
 Median (range) 0.084 (0.004–5.608)
The pretreatment NLR
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the initiation of chemotherapy. The serum CRP and ALB 
concentrations were measured using a chemilumines-
cent immunoassay (Wako, Osaka, Japan) according to the 
manufacturer’s protocol. The differential white blood cell 
count was analyzed using an XE-5000 hematology ana-
lyzer (Sysmex, Kobe, Japan) based on the manufacturer’s 
protocol. The CRP/ALB ratio was calculated from the 
preoperative blood samples by dividing the serum CRP 
level by the serum ALB level. The mGPS was defined 
according to the methods of a previous report (Petrelli 
et al. 2015), using the combination of the serum CRP and 
ALB levels: patients with a CRP level of <1.0 mg/dl were 
allocated a score of 0; those in whom the CRP and ALB 
levels were ≥1.0 mg/dl and ≥3.5 g/dl, respectively, were 
allocated a score of 1; and those in whom the CRP and 
ALB levels were ≥1.0 mg/dl and ALB < 3.5 g/dl, respec-
tively, were allocated a score of 2. The neutrophil to lym-
phocyte ratio (NLR) was calculated from a blood sample 
by dividing the absolute neutrophil count by the absolute 
lymphocyte count.
Statistical analysis
The significance of the correlations between the pretreat-
ment CRP/ALB ratio and the clinicopathological charac-
teristics were analyzed using the χ2 test. The duration of 
survival was calculated according to the Kaplan–Meier 
method. Differences in the survival curves were assessed 
using the log-rank test. A multivariate analysis was per-
formed according to the Cox proportional hazard model. 
All of the statistical analyses were conducted using the 
SPSS software package for Windows (SPSS Japan, Tokyo, 
Japan). p values of <0.05 were considered to indicate sta-
tistical significance.
Ethical consideration
This research was conformed to the provisions of the 
Declaration of Helsinki in 1975. All patients were 
informed of the investigational nature of this study and 
provided written informed consent. This retrospective 
study was approved by the ethics committee of Osaka 
City University.
Results
Classifications according to the pretreatment inflammatory 
markers
We used the CRP/ALB ratio, which was a continuous 
variable, as the test variable and the 24-month survival 
(median survival time: 24  months) as the state variable. 
When we investigated the cut-off value for the CRP/ALB 
ratio using the receiver operating characteristic (ROC) 
curve, we found that the appropriate cut-off value for the 
CRP/ALB ratio was 0.183 (sensitivity: 53.5  %; specific-
ity: 72.1 %) (Fig. 1a). We therefore set 0.183 as the cut-off 
value and the patients were classified into the high-CRP/
ALB ratio (n  =  36) and low-CRP/ALB ratio (n  =  63) 
groups. Using the ROC curve in the same manner, we set 
the cut-off value for the NLR at 3.0 (sensitivity: 65.0  %, 
specificity: 78.0 %) (Fig. 1b). In accordance with the find-
ings of previous reports, the study population was clas-
sified into the patients with an mGPS of 0 or 1 and the 
Fig. 1 a A receiver operating characteristic curve analysis of the C-reactive protein to albumin (CRP/ALB) ratio in patients with unresectable 
metastatic colorectal cancer. Area under the curve = 0.655; 95 % confidence interval = 0.539–0.772; p = 0.013. b A receiver operating characteristic 
curve analysis of the neutrophil to lymphocyte ratio (NLR) in patients with unresectable metastatic colorectal cancer. Area under the curve = 0.701; 
95 % confidence interval = 0.582–0.820; p = 0.002
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patients with an mGPS of 2 (Sugimoto et al. 2012; Furu-
kawa et al. 2012).
The correlations between the pretreatment CRP/ALB ratio 
and the clinicopathological factors
The correlations between the pretreatment CRP/ALB 
ratio and the clinicopathological factors are shown in 
Table 2. The pretreatment CRP/ALB ratio had no signifi-
cant relationships with any of the clinicopathological fac-
tors except for the pretreatment mGPS and NLR.
The survival analysis based on the pretreatment 
inflammatory markers
The overall survival rate was significantly worse in the 
high pretreatment CRP/ALB ratio group than in the 
low pretreatment CRP/ALB ratio group (p  =  0.0009) 
(Fig. 2a). The overall survival rate was significantly worse 
in patients with an mGPS of 2 than in those with an 
mGPS of 0 or 1 (p =  0.0450) (Fig.  2b). The overall sur-
vival rate was significantly worse in the high neutrophil 
to lymphocyte ratio group than in the low neutrophil to 
lymphocyte group (p < 0.0001) (Fig. 2c).
The prognostic factors influencing long‑term survival
The correlations between overall survival and the vari-
ous clinicopathological factors are shown in Table  3. 
According to the results of a univariate analysis, over-
all survival showed significant relationships with the 
number of organs affected by metastasis (p  =  0.024), 
the use of a molecular targeted therapy (p  =  0.001), 
the pretreatment CRP/ALB ratio (p  =  0.001) and the 
pretreatment NLR (p  <  0.001). A multivariate analysis 
indicated that the use of a molecular targeted therapy 
(hazard ratio 0.341; 95  % confidence interval 0.186–
0.626; p  =  0.001), the pretreatment CRP/ALB ratio 
(hazard ratio 1.866; 95  % confidence interval 1.057–
3.295; p  =  0.031) and the pretreatment NLR (haz-
ard ratio 2.706; 95  % confidence interval 1.483–4.939; 
p  =  0.001) were independent prognostic factors for 
overall survival.
The survival analysis based on the pretreatment CRP/ALB 
ratio, limited to the patients with an mGPS of 0 or 1
We then performed a sub-analysis limited to patients 
with an mGPS of 0 or 1. Among these patients, the over-
all survival rate was significantly worse in the high-CRP/
ALB ratio group than in the low-CRP/ALB ratio group 
(p = 0.0048) (Fig. 2d).
The correlation between the normalization of the CRP/ALB 
ratio at eight weeks after chemotherapy and survival
We evaluated the prognostic significance of the normali-
zation of the CRP/ALB ratio at eight weeks after the ini-
tiation of chemotherapy. We categorized the patients into 
three groups according to their pretreatment and post-
treatment CRP/ALB ratio values. Patients with a low pre-
treatment CRP/ALB ratio were categorized into group A. 
Patients with a high pretreatment CRP/ALB ratio and a 
normalized CRP/ALB ratio at eight weeks after the ini-
tiation of chemotherapy were categorized into group B. 
Patients with high pretreatment and posttreatment CRP/
ALB ratio values were categorized into group C. The 
patients in group B tended to exhibit a better prognosis 
than those in group C (p = 0.0641) (Fig. 3).
Table 2 The correlations between  the pretreatment CRP/
ALB ratio and the clinicopathological factors
CRP/ALB ratio C-reactive protein to albumin ratio, CEA carcinoembryonic antigen, 
mGPS modified Glasgow prognostic score, NLR neutrophil to lymphocyte ratio
Pretreatment CRP/ALB ratio
Low High p value
Gender
 Male 36 21
 Female 27 15 1.000
Age
 <65 34 19
 ≥65 29 17 1.000
Location of primary tumor
 Colon 36 21
 Rectum 27 15 1.000
Detection of unresectable tumor
 Synchronous 34 25
 Metachronous 29 11 0.143
Histological type
 Well, moderately 51 27
 Poorly, mucinous 9 3 0.744
Peritoneal dissemination
 Negative 47 33
 Positive 16 3 0.061
The number of organs affected by metastasis
 One organ 36 18
 Multiple organs 27 18 0.534
Pretreatment CEA (ng/ml)
 ≤5 9 4
 >5 53 31 0.765
Molecular targeted therapy
 No 17 12
 Yes 46 24 0.503
Pretreatment mGPS
 0 63 6
 1 0 21
 2 0 9 <0.001
Pretreatment NLR
 <3 41 13
 ≥3 18 22 0.003
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Fig. 2 The Kaplan–Meier survival curves for overall survival. a The overall survival rate was significantly worse in the high-C-reactive protein to albu-
min (CRP/ALB) ratio group than in the low-CRP/ALB ratio group (p = 0.0009). b The overall survival rate was significantly worse in patients with a 
modified Glagow prognostic score (mGPS) of 2 than in those with an mGPS of 0 or 1 (p = 0.0450). c The overall survival rate was significantly worse 
in the high neutrophil to lymphocyte ratio (NLR) group than in the low NLR group (p < 0.0001). d Kaplan–Meier survival curves for overall survival in 
an analysis limited to the patients with a modified Glasgow prognostic score (mGPS) of 0 or 1. The overall survival rate was significantly worse in the 
high-C-reactive protein to albumin (CRP/ALB) ratio group than in the low-CRP/ALB ratio group (p = 0.0048)
Table 3 The correlations between overall survival and various clinicopathological factors
CEA carcinoembryonic antigen, CRP/ALB ratio C-reactive protein to albumin ratio, NLR neutrophil to lymphocyte ratio
Univariate analysis Multivariate analysis
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
Gender (female vs. male) 1.473 0.895–2.423 0.128
Age (≥65 vs. <65) 1.492 0.907–2.454 0.115
Location of primary tumor (colon vs. rectum) 1.273 0.769–2.108 0.348
Detection of unresectable tumor (synchronous vs. metachronous) 1.595 0.946–2.688 0.080 1.099 0.595–2.030 0.763
Histological type (poorly, mucinous vs. well, moderately) 1.417 0.688–2.916 0.344
Peritoneal dissemination (yes vs. no) 1.124 0.609–2.075 0.708
The number of organs affected by metastasis (≥2 vs. <2) 1.775 1.078–2.923 0.024 1.115 0.622–1.997 0.715
Pretreatment CEA (>5 ng/ml vs. ≤5 ng/ml) 2.193 0.940–5.113 0.069 1.370 0.526–3.571 0.520
Molecular targeted therapy (yes vs. no) 0.391 0.227–0.676 0.001 0.341 0.186–0.626 0.001
Pretreatment CRP/ALB ratio (>0.183 vs. ≤0.183) 2.301 1.390–3.807 0.001 1.866 1.057–3.295 0.031
Pretreatment NLR (>3 vs. ≤3) 3.777 2.191–6.511 <0.001 2.706 1.483–4.939 0.001
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Discussion
There have been various studies on the close relationship 
between inflammation and cancer since the relationship 
was first reported by Virchow in 1863 (Mantovani et al. 
2008; Balkwill and Mantovani 2001). Recently, inflamma-
tion has been widely recognized to contribute to cancer 
progression and various inflammatory markers, such as 
the NLR, CRP, GPS and mGPS have been reported to be 
correlated with the survival of patients with CRC (Shib-
utani et  al. 2013, 2014; McMillan et  al. 2007; Sugimoto 
et al. 2012; Furukawa et al. 2012).
Inflammation induces an increase in the levels of 
cytokines, which play an important role in tumor pro-
liferation, progression, invasion and metastasis, as well 
as in resistance to chemotherapy (Colotta et  al. 2009; 
Coussens and Werb 2002; Heikkilä et  al. 2007). There-
fore, inflammatory markers are considered to reflect the 
momentum of cancer growth. Furthermore, the levels 
of systemic inflammatory markers have been reported 
to correlate with tumor volume (Shibutani et al. 2015b). 
In this way, inflammatory markers are considered to be 
useful for predicting and monitoring the therapeutic out-
come in patients with malignancies.
The CRP/ALB ratio was primarily investigated for the 
purpose of predicting mortality in patients with sepsis. 
The CRP/ALB ratio was also applied to predicting the 
prognosis of patients with cancer and its usefulness has 
been reported in patients with various cancers, such as 
hepatocellular carcinoma, esophageal cancer and lung 
cancer (Kinoshita et al. 2015; Xu et al. 2015; Zhou et al. 
2015). In previous reports, the CRP/ALB ratio was shown 
to have an outstanding prognostic value in comparison to 
other established inflammation-based prognostic mark-
ers (Kinoshita et  al. 2015; Xu et  al. 2015). Although the 
area under curve (AUC) value of the CRP/ALB ratio 
was lower than that of the NLR, the CRP/ALB ratio was 
shown to be a valuable marker and was thus found to be 
sufficient for predicting survival in the present study.
As Casadei Gardini reported, the serum CRP concen-
tration alone is also significantly correlated with the sur-
vival (Casadei Gardini et al. 2016). We came to the same 
conclusion based on the findings in our previous study 
(Shibutani et al. 2015b). However, Ranzani reported that 
the CRP/ALB ratio was more closely correlated with sur-
vival than the CRP values alone (Ranzani et al. 2013). By 
combining the CRP and albumin values, which have both 
been reported to be independent prognostic factors for 
various types of cancer, the CRP/ALB ratio is believed to 
be a more useful marker.
The mGPS, which has been reported to be a useful 
prognostic marker in patients with CRC, is similar to the 
CRP/ALB ratio, as both results can be calculated from 
the serum CRP and albumin concentration. However, the 
majority of the patients are classified with an mGPS of 0 
or 1, which is associated with a better prognosis (Sugi-
moto et  al. 2012; Furukawa et  al. 2012). In the present 
study, approximately 90 % of the patients were found to 
have an mGPS of 0 or 1. For this reason, most patients 
could not be classified by the mGPS. On the other hand, 
the patients who had an mGPS of 0 or 1 could be classi-
fied into two groups according to their CRP/ALB ratios 
and significant differences were observed between the 
two groups. It can therefore be said that the CRP/ALB 
ratio is a more accurate prognostic marker than the 
mGPS.
Moreover, the normalization of the CRP/ALB ratio at 
eight weeks after the initiation of chemotherapy tended 
to be correlated with an improvement in overall survival. 
Based on this result, the CRP/ALB ratio is considered 
to be a useful marker for monitoring the effectiveness 
of chemotherapy as well as for predicting survival. On 
the other hand, it has been reported that there is no 
relationship between the normalization of the NLR and 
survival, because the value is easily affected by chem-
otherapy-induced myelosuppression (Shibutani et  al. 
2015a). Therefore, the CRP/ALB ratio was believed to 
be superior to the NLR for evaluating the efficacy of 
chemotherapy. Although previous studies have primar-
ily focused on the prognostic significance of the pretreat-
ment CRP/ALB ratio, in the present study, the CRP/ALB 
ratio was revealed to be a useful marker for monitoring 
the effectiveness of chemotherapy as well as for predict-
ing survival.
Although we set 0.183 as the CRP/ALB ratio cut-off 
value according to the results of the ROC analysis, other 
Fig. 3 Overall survival according to the combination of the pretreat-
ment and posttreatment C-reactive protein to albumin (CRP/ALB) 
ratio values. The prognosis of the patients in group B tended to be 
better than that in the patients of group C (p = 0.0641)
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studies have used various cut-off values. Because the 
inflammatory markers were reported to be associated 
with the degree of tumor progression, such as the TNM 
stage (Shibutani et al. 2013; Xu et al. 2015; Ishizuka et al. 
2016), the appropriate cut-off value may change accord-
ing to the background characteristics of the patients.
The present study is associated with some possible lim-
itations. First, we evaluated a relatively small number of 
patients and the study design was retrospective in nature. 
Second, comorbidities that may have affected systemic 
inflammation and the serum albumin concentration 
(such as infection, ischemia, acute coronary disease, liver 
cirrhosis, and nephrotic syndrome) were not taken into 
consideration. A large prospective study should therefore 
be performed to confirm our findings.
Conclusions
The CRP/ALB ratio is a useful marker not only for pre-
dicting survival, but also for monitoring chemotherapeu-
tic effectiveness in patients with unresectable metastatic 
colorectal cancer who receive palliative chemotherapy.
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